Article Details

Graphite pulls off $238M IPO to sketch out path to clinic for gene-editing sickle cell treatment

Retrieved on: 2021-06-25 15:11:15

Tags for this article:

Click the tags to see associated articles and topics

Graphite pulls off $238M IPO to sketch out path to clinic for gene-editing sickle cell treatment. View article details on hiswai:

Excerpt

... Wall Street welcome as it rustles up capital to fund gene-editing treatments for sickle cell disease, an immune system disorder and Gaucher disease.

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up